Abstract Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells
accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First …

Cancer immunotherapy has emerged as an effective therapeutic strategy to treat cancer.
Among diverse immune populations, invariant natural killer T (iNKT) cells have shown …

Antitumor immune responses induced by immune checkpoint inhibitors anti-PD-1 or anti-PD-
L1 have been used as therapeutic strategies in advanced non-small cell lung cancer …

Background: Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1
(PD-1)/programmed death-ligand 1 (PD-L1), have been widely applied in clinical and …

The major suppressive immune cells in tumor sites are myeloid derived suppressor cells
(MDSCs), tumor‐associated macrophages (TAMs), and Treg cells, and the major roles of …

Lung cancer is amongst the most pervasive malignancies having high mortality rates. It is
broadly grouped into non-small-cell lung cancer (NSCLC) and small-cell lung cancer …

Antibodies targeting the immune checkpoint inhibitor, programmed cell death 1 (PD-1), have
provided a breakthrough in the treatment of lung cancer. However, the function of PD-1 in …

Introduction: Small cell lung cancer (SCLC) is a highly malignant disease with a dismal
prognosis that is currently being tested for theclinical activity of checkpoint inhibitors. SCLC …

Inhibition of immune checkpoint proteins like programmed death 1 (PD-1) is a promising
therapeutic approach for several cancers, including non-small cell lung cancer (NSCLC) …

Combination therapy has gained a lot of attention thanks to its superior activity against
cancer. In the present study, we report a cRGD-targeted liposomal preparation for co …